Back to Blog
    partnerships

    Building in Public: BioCompute's MaRS Momentum Journey

    Paul Goldman·CEO, iTmethods / BioCompute
    March 16, 2026
    4 min read
    PG
    Paul Goldman
    CEO, iTmethods

    Why MaRS Momentum

    When we applied to MaRS Momentum, we weren't looking for just another accelerator badge. MaRS represents something specific in the Canadian and global innovation ecosystem: deep expertise at the intersection of technology and life sciences, combined with a network that includes major health systems, regulatory bodies, and institutional investors.

    For BioCompute—a platform that sits at the exact intersection of AI governance and life sciences compliance—MaRS Momentum is the ideal growth partner.

    What MaRS Brings to BioCompute

    The Momentum program gives us access to three critical resources:

    Domain Expertise. MaRS has one of the deepest benches in health innovation advisory. Their team has guided dozens of health-tech companies through regulatory pathways, institutional sales cycles, and clinical validation processes. For a platform like BioCompute, where understanding the regulatory landscape is as important as the technology itself, this mentorship is invaluable.

    Network Effects. MaRS connects us to Canada's largest health systems, including University Health Network, SickKids, and Sunnybrook—potential design partners who can validate BioCompute's Evidence Books against real clinical AI deployments.

    Investor Access. The Momentum program positions BioCompute in front of investors who understand the long sales cycles and deep domain expertise required to build enterprise health-tech. These aren't generalist VCs—they're investors who understand why regulatory compliance infrastructure is a multi-billion-dollar opportunity.

    Building in Public

    We believe in transparency. As we progress through the Momentum program, we'll be sharing our journey publicly: the wins, the challenges, the pivot points, and the lessons learned. Life sciences AI governance is a nascent space, and we think the entire ecosystem benefits when builders share their experiences openly.

    Follow along on LinkedIn and right here on our blog.


    Interested in BioCompute's journey? Become a design partner and help shape the future of life sciences AI compliance.

    PG
    Paul Goldman
    CEO, iTmethods

    20+ years building enterprise technology platforms for regulated industries. Leading the Fortress Family — Reign, Forge, BioCompute — to govern AI at enterprise scale.

    MaRS
    Momentum
    Canada
    Startup
    Growth
    Share:

    Ready to build your evidence infrastructure?

    Join our design partner program and get early access to BioCompute's sovereign AI platform for life sciences.

    Newsletter

    Sign Up for Updates

    AI governance insights for life sciences leaders.

    No spam. Unsubscribe anytime.